Sanofi-Aventis 2Q08

NOTE: All amounts in Euros

2Q Revenues: EUR 6.7 billion (-4%)

2Q Earnings: EUR 1.0 billion*

YTD Revenues: EUR 13.6 billion (-4%)

YTD Earnings: EUR 2.3 billion*

Comments: Pharmaceutical revenues were up 4% for the quarter to EUR 6,032, and up 2% for HY08 to EUR 12,421. Lantus sales grew 27% in 2Q08 to EUR 576, while Lovenox sales only increased 5% to EU 637. Overall Ambien sales continued to crater, dropping 22% in 2Q08 to EUR 191. Ambien group sales are down 50% for HY08. Vaccine sales were up 17% to EUR 657, driven by 78% growth in influenza vaccines and 18% growth in adult booster vacines. For HY08, vaccine sales rose 10% to EUR 1,205. Overall sales in 2Q08 grew 12% in non-U.S./non-Europe regions; those areas were up 7% and 1%, respectively.

* Announcement did not include figures for consolidated earnings for 2Q07 or HY07, instead releasing figures that excluded certain costs.

News from our sister sites